Results 171 to 180 of about 101,286 (277)

Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer. [PDF]

Sci Rep
Zhao S, Kang S.
europepmc   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

A Case of Metastatic Renal Cell Carcinoma Developing Isolated Adrenocorticotropic Hormone (ACTH) Deficiency During Nivolumab Therapy. [PDF]

Cureus
Enoki M, Yamanaka K, Kawashima A, Fukuhara S, Nonomura N.   +4 more
europepmc   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab. [PDF]

Sci Rep
Fiala O, Rejleková K, Buchler T, Študentová H, Poprach A, Vočka M, Hošek P, Kopecký J, Matějů M, Zemánková A, Spisarová M, Tkadlecová M, Priester P, Kouřil J, Lohynská R, Grmelová L, Savka A, Štefániková K, Obertová J, Šiková D, Stránský P, Melichar B, Palacka P.   +22 more
europepmc   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma. [PDF]

J Cancer Res Clin Oncol
Oksuz S, Kinikoglu O, Ozkerim U, Isik D, Surmeli H, Ay S, Gundogdu UD, Basoglu T, Odabas H, Turan N.   +9 more
europepmc   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Spatial Profiling and Prognostic Role of Tumor-Infiltrating CD8+ T and CD20+ B Cells in Metastatic Clear Cell Renal Cell Carcinoma Treated with Sequential Tyrosine Kinase Inhibitors and Nivolumab. [PDF]

J Cancer
Trailin A, Červenková L, Hošek P, Pivovarčíková K, Tkadlecová M, Stránský P, Hemminki K, Fiala O.   +7 more
europepmc   +1 more source

Making sense of TILs: recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma

Histopathology, EarlyView.
This review examines the role of tumour‐infiltrating lymphocytes (TILs) in gastro‐oesophageal carcinoma (GEC), focusing on their composition, clinical relevance and therapeutic utility. It proposes a framework for standardised evaluation and reporting of TILs, addressing GEC‐specific pathology challenges to support the widespread use and validation of ...
Ylva A Weeda, Roberto Salgado, Filip van Herpe, Daniel Sur, Michael Vieth, Sherene Loi, Ahmad P Tafti, Hardas Alexandros, Akira I Hida, Amarpreet Bhalla, Andrey I Khramtsov, Anna Ehinger, Atsushi Tanaka, Balazs Acs, Caner Ercan, Cornelia M Focke, Daniel Ehinger, Dan Huang, Galina F Khramtsova, Haruto Nishida, Nianyi Li, Nickolas Littlefield, Sanna Steen, Selim Sevim, Shin Ichihara, Shinnosuke Morikawa, Stefan Michiels, Thomas Papathomas, Toshihiro Haga, Qiangqiang Gu, Weiqi Sheng, Hoel Kervadec, Hugo M Horlings, Francisco Sanchez‐Vega, Yelena Y Janjigian, Myriam Chalabi, Hanneke W M van Laarhoven, Liudmila L Kodach, Sybren L Meijer   +38 more
wiley   +1 more source